Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

5 May 2020

Abstract excerpt

Abstract NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds to chromatin through its two bromodomains, and NUT recruits the p300 histone acetyltransferse (HAT) to activate transcription of oncogenic target genes. BET-selective bromodomain inhibitors have demonstrated on-target activity in patients with NMC,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32371576
DOI: 10.1158/1535-7163.mct-20-0087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734PMID 32371576Read ↗

Pathogenesis of NUT Midline CarcinomaSemantic proximity Read ↗

NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatmentSemantic proximity Read ↗

SETD2 and miR-21 as therapeutic targets for NUT midline carcinomaSemantic proximity Read ↗

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.Semantic proximity Read ↗

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesSemantic proximity Read ↗

NUT Carcinoma—An Underdiagnosed MalignancySemantic proximity Read ↗

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genesSemantic proximity Read ↗

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionSemantic proximity Read ↗

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinomaSemantic proximity Read ↗

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaSemantic proximity Read ↗

Novel BRD4–NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinomaSemantic proximity Read ↗

SETD2 Deficiency and miR-21: Potent Therapeutic Targets in NUT Midline CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.